Appearance of thymosin alpha 1 in supernatants of monocytes incubated with prothymosin alpha.
Frillingos. S S; Seferiadis. K K; Papanastasiou. M M; Baxevanis. C N CN; Frangou-Lazaridis. M M; Economou. M M; Papamichail. M M; Tsolas. O O
Key Findings
- Prothymosin alpha contains the full thymosin‑alpha‑1 sequence and can be processed by monocytes to release it into the surrounding fluid.
- The release of thymosin‑alpha‑1 depends on new RNA and protein synthesis, as shown by inhibition with actinomycin D and cycloheximide.
- The released thymosin‑alpha‑1, possibly together with HLA‑DR, stimulates proliferation of T‑cells in vitro.
Practical Outcomes
- For biohackers, the finding hints that boosting prothymosin alpha levels might increase endogenous thymosin‑alpha‑1 and support immune health, but because the evidence is limited to cell cultures, there’s no clear dosage or protocol for humans yet.
Summary
The study shows that when human blood monocytes are exposed to prothymosin alpha, they cut out and release the short peptide thymosin‑alpha‑1, which can help T‑cells grow. This process needs the cells to make new proteins and can be blocked by certain inhibitors. The work is done in a petri dish, not in people, so it’s more of a basic science clue than a ready‑to‑use supplement tip.
Abstract
Prothymosin alpha, a polypeptide of 109 to 111 amino acid residues, contains the entire thymosin alpha 1 sequence (residues 1-28) at its amino terminal. Human peripheral blood monocytes incubated with prothymosin alpha release thymosin alpha 1 in the culture supernatants. In addition total RNA is found to increase. The production of thymosin alpha 1 involves de novo protein synthesis as shown by the kinetics of this release and its inhibition by actinomycin D and cycloheximide. Thymosin alpha 1 release, possibly in association with HLA-DR, stimulates the proliferation of the T cell population.
Study Information
pubmed
1992
10.1016/0003-9861(92)90570-m